Background
==========

Breast cancer is the most commonly diagnosed malignancy among women in developed countries \[[@B1]-[@B3]\], and in some developing countries \[[@B4]-[@B6]\]. According to the report of the Iranian Centre for the Prevention and Control of Disease, Ministry of Health and Medical Education, 2000, Iran; breast cancer is the most prevalent cancer among Iranian women and accounts for 21.4% of all malignancies.

The prevalence of breast cancer in Europe and the USA is estimated between 8 to 10%. However, the lowest prevalence is seen in Asian countries, at about 1% \[[@B7]\]. In Iran the prevalence of breast cancer was reported as 6.7/1000 in 2002, which is even less than this \[[@B8]\]. While there has been substantial research published on risk factors and prognostic factors for breast cancer in general, research specific to Iran is sparse. Further, the association between breast cancer survival and socio-demographic and pathologic factors has been widely studied but the majority of these studies are from developed countries.

Iran has a total population of just over 70 million and almost all studies of breast cancer in Iran are from the capital, Tehran with a population of approximately 14 million. Most of these studies have not focused on survival and prognostic factors. To our knowledge, only two studies from Tehran have investigated breast cancer survival \[[@B9],[@B10]\]. Southern Iran has a population of approximately 4 million and to date no study has determined breast cancer survival in this region or explored the relationships between the survival and socio-demographic and pathological factors. This paper presents the results of a study which fills this gap by determining five-year breast cancer survival for women with breast cancer in Southern Iran, and the impact of 44 explanatory factors.

Ethical approval for this study was obtained from the Research Ethics Committee of Shiraz University of Medical Sciences, Iran, and the Research Ethics Committee of the School of Health Sciences and Social Care of Brunel University, UK.

Methods
=======

This study used patients\' records from Shiraz University Cancer Registry Centre, which is a hospital-based registry in a tertiary care centre which delivers oncology services to a population of approximately four million. This is the only centre which delivers oncology services in Southern Iran. Therefore, most probably all cancer patients come to this hospital for treatment. However a few of them may travel to other centers for treatment. The Cancer Registry was started on 1 January 2000 and so this study includes women who were diagnosed with breast cancer between 1 January 2000 and 31 Dec. 2005. During that period, of the 6253 patients diagnosed with ten most common cancers in the area, 1192 were registered as having female breast cancer. Thirty women were excluded due to previous breast cancer (23), ductal carcinoma in situ (2), and other previous cancers (5). In addition, 14 women with bilateral tumours were excluded due to the small numbers. Thus, the study population comprised 1148 women who were diagnosed with a first primary invasive breast malignancy and who underwent breast surgery including axillary dissection.

All patients were followed-up at regular three month intervals for the first year following diagnosis and had regular six month follow-ups thereafter. The last date of follow-up was 29^th^July 2006. All subjects in this study underwent surgery and received radiation and all except a very small proportion received chemotherapy. These three treatment options have been offered in three sequences: surgery followed by chemotherapy and then by radiation, chemotherapy followed by surgery and then by radiation, and surgery followed only by radiation, in common with current practice in this region. About 82% received surgery followed by chemotherapy and then by radiation, 16% chemotherapy followed by surgery and then by radiation, and 2% received surgery followed only by radiation. At the time of diagnosis all patients were evaluated for metastasis to five distant sites: bone, liver, lung, brain, and ovary.

The main objective of this study was to investigate the impact of a wide range of factors on breast cancer survival. Therefore, the only outcome considered here is survival. All variables recorded at the cancer registry (44) were used in this study. The 44 explanatory variables divide naturally into three groups: socioeconomic or demographic, clinical/pathological factors, and distant metastases.

The association between each of the explanatory variables and outcome was assessed in turn using Cox\'s regression (unifactorial analysis).

Variables that were significantly associated with survival were considered firstly in each of the three conceptual groups: socioeconomic and demographic factors together, clinical/pathological factors, and distant metastases. Each model included all variables from the particular group that were statistically significant unifactorially, and then the variable that had the greatest regression estimate p-value was removed from the model. This process continued by remodeling and repeating removal of the next variable with the greatest p-value until all variables left in the model had p-value less than 0.05. A final model was fitted by combining all variables which were statistically significant in the three groups separately.

The proportional hazards assumption was examined at all stages in two ways: i) visually by inspecting graphs of the cumulative baseline functions against log survival time and ii) by a test based on the Schoenfeld residuals.

The results are presented as hazard ratios and 95% confidence intervals. All analysis was conducted using Stata v9.

Results
=======

Impact of socio-demographic factors on survival
-----------------------------------------------

Of the 1148 patients included in the analysis 859 were alive at the end of follow-up, 269 had died, and 20 were lost to follow-up. Median follow-up time, from first pathological diagnosis until the time of death or the end of study, was 34 months. Mean age at diagnosis was 47 years (ranged from 19 to 86 years).

In unifactorial analysis of all socioeconomic and demographic factors, only family income and smoking were significantly associated with survival. (Table [1](#T1){ref-type="table"}) These two factors together were entered into the first model and both remained significant. Compared to the patients with a low family income those with a higher family income were at 54% lower risk of death. (Table [2](#T2){ref-type="table"}) Smokers were also at a 40% higher risk of death compared to non-smokers.

###### 

Uni-factorial analyses and distribution of socio-demographic factors

  Unifactorial analysis                               Distribution of factors             
  ---------------------------- ---------------------- ------------------------- --------- ------
                               Hazard ratio (95%CI)   p                         Numbers   \%
                                                                                          
  Area of residence                                                             1148\*    100
   Affluent                    1                      0.179                     213       19
   Middle                      1.12 (0.79--1.58)                                590       51
   Deprived                    1.36 (0.95--1.94)                                345       30
                                                                                          
  Family income                                                                 1143      99
   Low & poor                  1                      0.031                     426       37
   Moderate                    0.88 (0.69--1.13)                                669       58
   High                        0.44 (0.22--0.87)                                48        4
                                                                                          
  Occupation                                                                    1148      100
   Housewife                   1                      0.853                     898       78
   Non-manual                  0.92 (0.67--1.28)                                199       17
   Manual                      1.07 (0.63--1.80)                                51        4
                                                                                          
  Education                                                                     661       57
   Illiterate                  1                      0.939                     203       18
   Primary                     1.01 (0.65--1.58)                                223       19
   High school                 1.15 (0.71--1.85)                                148       13
   University                  1.00 (0.58--1.74)                                87        7
                                                                                          
  Smoking                                                                       1145      100
   Non-smoker                  1                      0.009                     904       79
   Smoker                      1.44 (1.09--1.89)                                241       21
                                                                                          
  Marital status                                                                1147      100
   Single                      1                      0.056                     104       9
   Married                     0.64 (0.44--0.93)                                936       82
   Divorced & Widowed          0.77 (0.46--1.28)                                107       9
                                                                                          
  Blood group                                                                   408       36
   O                           1                      0.739                     153       13
   A                           1.18 (0.71--1.95)                                105       9
   B                           1.32 (0.80--2.19)                                100       9
   AB                          1.08 (0.53--2.20)                                45        4
                                                                                          
  BMI (Body Mass Index)                                                         951       83
   \<25                        1                      0.784                     509       44
   25--30                      1.10 (0.82--1.47)                                317       28
   \>30                        1.09 (0.72--1.66)                                125       11
                                                                                          
  No. of children                                                               1143      100
   ≤ 3                         1                      0.218                     571       50
   4--8                        0.95 (0.74--1.22)                                518       45
   \>8                         1.87 (1.18--2.96)                                54        5
                                                                                          
  Age at diagnosis                                                              1118      97
   ≤ 35 years                  1                      0.499                     172       15
   36--49 years                0.96 (0.67--1.37)                                519       45
   50--64 years                1.02 (0.69--1.50)                                342       30
   ≥ 65 years                  1.35 (0.82--2.22)                                85        7
                                                                                          
  Age at first pregnancy                                                        122       11
   ≤ 18 years                  1                      0.081                     55        5
   19--25 years                0.30 (0.08--1.06)                                47        4
   \>25 years                  0.21 (0.03--1.66)                                20        2
                                                                                          
  OCP use                                                                       255       22
   ≤ 3 years                   1                      0.869                     80        7
   \>3 years                   0.96 (0.59--1.57)                                175       15
                                                                                          
  Ethnicity                                                                     1140      99
   Fars                        1                      0.821                     1006      88
   Non-Fars                    1.04 (0.73--1.48)                                134       12
                                                                                          
  Religion                                                                      1147      100
   Islam (Shia)                1                      0.931                     1031      90
   Islam (Sunni)               0.93 (0.65--1.32)                                110       9.5
   Others                      1.23 (0-.)                                       6         0.05
                                                                                          
  Menarche age                                                                  938       82
   ≤ 13 years                  1                      0.934                     561       49
   \>13 years                  0.99 (0.75--1.30)                                377       33
                                                                                          
  History of BC in SDR                                                          1148      100
   No                          1                      0.758                     996       87
   Yes                         0.94 (0.65--1.36)                                152       13
                                                                                          
  History of BC in FDR                                                          1148      100
   No                          1                      0.22                      881       77
   Yes                         0.83 (0.62--1.11)                                267       23
                                                                                          
  Duration of breast feeding                                                    205       18
   ≤ 3 years                   1                      0.175                     78        7
   4--6 years                  2.03 (0.96--4.29)                                68        6
   \>6 years                   1.62 (0.71--3.69)                                59        5

Abbreviations: OCP = Oral Contraceptive pill, BC = Breast Cancer, FDR = First Degree Relatives, SDR = Second Degree Relatives

\* Total number available of 1148 subjects

###### 

Multi-factorial analysis by three conceptual groups and final model

  Variables from the other three multifactorial analyses   Result of final model                                         
  -------------------------------------------------------- ----------------------- ------- ------ ---------------------- -------
                                                           Hazard ratio (95%CI)    P       \*\*   Hazard ratio (95%CI)   p
                                                                                                                         
  Family income                                                                                                          
   Low & poor                                              1                       0.039   99%                           
   Moderate                                                0.90 (0.70--1.15)                                             
   Good                                                    0.46 (0.23--0.90)                                             
                                                                                                                         
  Smoking                                                                                                                
   Non-smoker                                              1                       0.016   99%                           
   Smoker                                                  1.40 (1.07--1.86)                                             
                                                                                                                         
  Metastasis to bone                                                                                                     
   No                                                      1                       0.000   100%                          
   Yes                                                     2.25 (1.43--3.52)                                             
                                                                                                                         
  Metastasis to lung                                                                                                     
   No                                                      1                       0.000   100%                          
   Yes                                                     3.21 (1.70--6.05)                                             
                                                                                                                         
  Tumour size                                                                                                            
   ≤ 2 cm                                                  1                       0.000   88%    1                      0.000
   \>2 & \<5 cm                                            1.43 (0.97--2.09)                      1.43 (0.97--2.09)      
   ≥ 5 cm                                                  2.07 (1.39--3.09)                      2.07 (1.39--3.10)      
                                                                                                                         
  Tumour grade                                                                                                           
   Well-differentiated                                     1                       0.000   88%    1                      0.000
   Moderately-differentiated                               1.30 (0.88--1.93)                      1.30 (0.88--1.93)      
   Poorly-differentiated                                   2.33 (1.52--3.37)                      2.33 (1.52--3.57)      
                                                                                                                         
  No. of involved lymph nodes                                                                                            
   0                                                       1                       0.000   88%    1                      0.000
   1--5                                                    2.96 (1.78--4.94)                      2.96 (1.78--4.94)      
   6--10                                                   5.29 (3.11--9.01)                      5.29 (3.11--9.01)      
   11--15                                                  8.29 (4.98--13.80)                     8.29 (4.98--13.80)     
   \>15                                                    14.96 (8.83--25.33)                    14.96 (8.83--25.33)    
                                                                                                                         
  Lymph node ratio                                                                                                       
   0                                                       1                       0.000   88%    1                      0.000
   \> 0 &≤ .3                                              2.02(1.30--3.13)                       2.03 (1.09--3.76)      
   \> .3 &≤ .6                                             4.84 (2.72--8.60)                      4.84 (2.72--8.60)      
   \> .6 &\< 1                                             9.30 (5.48--15.80)                     9.30 (5.48--15.80)     
   1                                                       15.31 (8.89--26.33)                    15.31 (8.90--26.34)    

\*\* Proportion of subjects in multifactorial analysis

Impact of distant metastases on survival
----------------------------------------

Metastases to liver, lung and bone were all significantly associated with poorer survival in the unifactorial analyses (Table [3](#T3){ref-type="table"}). Metastases to bone and lung remained significant in the multifactorial model. Compared to the patients without distant metastasis those with lung metastasis had just over three times, and those with bone metastasis had just over twice the risk of death (Table [2](#T2){ref-type="table"}).

###### 

Uni-factorial analysis and distribution of distant metastases

  Unifactorial analysis   Distribution of factors                     
  ----------------------- ------------------------- ------- --------- ------
                          Hazard ratio (95%CI)      P       numbers   \%
                                                                      
  Metastasis to bone                                        1148      100
   No                     1                         0.001   1110      97
   Yes                    2.18 (1.39--3.41)                 38        3
                                                                      
  Metastasis to liver                                       1148      100
   No                     1                         0.001   1134      99
   Yes                    2.80 (1.48--5.27)                 14        1
                                                                      
  Metastasis to lung                                        1148      100
   No                     1                         0.001   1134      99
   Yes                    3.06 (1.62--5.76)                 14        1
                                                                      
  Metastasis to brain                                       1148      100
   No                     1                         0.283   1142      99.5
   Yes                    2.14 (0.53--8.63)                 6         0.5

Impact of clinical/pathological factors on survival
---------------------------------------------------

Of 15 clinical/pathological factors, greater tumour size and higher grade, tumour calcification and necrosis, skin and nipple involvement, vascular and lymphatic invasion, higher number of excised and involved nodes, greater lymph node ratio (LNR), treatment, and type of surgery were significantly associated with poorer survival in the unifactorial analyses (Table [4](#T4){ref-type="table"}). The factors that remained significant were tumour size, histological grade, number of involved nodes, and lymph node ratio. Patients with tumour size 5 cm and above had a two-fold increase in risk of death compared to the patients with tumour size 2 cm and less. Patients with poorly differentiated tumour grades had a doubling of risk of death compared to those with well differentiated tumour grades. There was a steady rise in risk with increased number of involved nodes ranging from a three-fold to a fifteen-fold increase in risk compared to node negative patients (Table [2](#T2){ref-type="table"}). Hazard ratios increased steadily as the lymph node ratio increased with the hazard being greatest for patients with a ratio of one compared with zero.

###### 

Uni-factorial analysis and distribution of clinico-pathological factors

  Unifactorial analysis         Distribution of factors                     
  ----------------------------- ------------------------- ------- --------- -----
                                Hazard ratio (95%CI)      p       numbers   \%
                                                                            
  Tumour side                                                     1064      93
   Right                        1                         0.562   565       49
   Left                         1.08 (0.84--1.39)                 499       4
                                                                            
  Tumour location                                                 440       38
   Lateral                      1                         0.258   322       28
   Medial                       0.75 (0.42--1.36)                 68        6
   Central                      0.60 (0.30--1.97)                 50        4
                                                                            
  Tumour size                                                     1055      92
   ≤ 2 cm                       1                         0.000   298       26
   \>2 & \<5 cm                 1.82 (1.30--2.70)                 523       46
   ≥ 5 cm                       3.04 (2.05--4.50)                 234       20
                                                                            
  Tumour grade                                                    1059      92
   Well-differentiated          1                         0.000   250       22
   Moderately-differentiated    1.89 (1.28--2.78)                 637       55
   Poorly-differentiated        4.53 (2.99--6.86)                 172       15
                                                                            
  Nuclear grade                                                   140       12
   Low                          1                         0.068   33        3
   Intermediate                 10.88 (1.00--80.75)               91        8
   High                         5.70 (0.59--54.90)                16        1
                                                                            
  Co-morbidity                                                    352       31
   GI&Respiratory               1                         0.433   37        3
   Cardiovascular               0.92 (0.44--1.95)                 122       11
   Psycho.&Neurological         0.69 (0.28--1.57)                 55        5
   Gynaecologic                 1.42 (0.61--3.29)                 39        3
   Endocrine&Metabolic          1.13 (0.55--2.33)                 99        9
                                                                            
  No. of stillbirths                                              1097      96
   0                            1                         0.581   997       87
   1--3                         1.19 (0.78--1.83)                 92        8
   \>3                          1.48 (0.47--4.62)                 8         1
                                                                            
  No. of abortions                                                1106      96
   0                            1                         0.525   819       71
   1--3                         0.85 (0.64--1.14)                 269       23
   \>3                          0.80 (0.30--2.15)                 18        2
                                                                            
  Histological type                                               1062      93
   IDC                          1                         0.086   942       82
   ILC                          0.68 (0.31--1.55)                 33        3
   Med.C                        0.35 (0.14--0.84)                 60        5
   MLDC                         1.55 (0-.)                        3         \<1
   Muc.C                        0.65 (0.09--4.62)                 6         \<1
   IPC                          1.33 (0.42--4.15)                 10        1
   Met.C                        3.31 (1.05--10.39)                8         1
                                                                            
  No. of excised lymph nodes                                      1048      91
   0                            1                         0.007   20        2
   1--10                        1.48 (0.46--4.74)                 263       23
   11--20                       1.93 (0.61--6.09)                 553       48
   21--30                       2.29 (0.713--7.37)                189       16
   \>30                         4.67 (1.28--17.03)                23        2
                                                                            
  Lymph node ratio                                                1027      89
   0                            1                         0.000   331       29
   \>0 & ≤ .3                   1.98 (1.06--3.66)                 246       21
   \>.3 & ≤ .6                  5.24 (2.96--9.29)                 156       14
   \>.6 & \< 1                  11.26 (6.68--18.96)               185       16
   1                            18.87 (11.09--32.08)              109       9
                                                                            
  No. of involved lymph nodes                                     1046      91
   0                            1                         0.000   349       30
   1--5                         3.03 (1.82--5.04)                 346       30
   6--10                        6.59 (3.89--11.15)                146       13
   11--15                       10.16 (6.13--16.84)               123       11
   \>15                         18.78 (11.21--31.45)              82        7
                                                                            
  Tumour calcification                                            1022      89
   No                           1                         0.000   740       64
   Yes                          1.67 (1.28--2.19)                 282       25
                                                                            
  Tumour necrosis                                                 317       28
   No                           1                         0.017   157       14
   Yes                          1.82 (1.11--2.97)                 160       14
                                                                            
  Nipple involvement                                              995       87
   No                           1                         0.000   887       77
   Yes                          1.84 (1.32--2.57)                 108       10
                                                                            
  Skin involvement                                                1013      88
   No                           1                         0.000   946       82
   Yes                          2.06 (1.39--3.05)                 67        6
                                                                            
  Vascular invasion                                               1035      90
   No                           1                         0.000   604       53
   Yes                          1.90 (1.47--2.46)                 431       37
                                                                            
  Lymphatic invasion                                              1006      88
   No                           1                         0.000   419       36
   Yes                          3.73 (2.67--5.20)                 587       52
                                                                            
  Treatment                                                       1134      99
   S&C&R                        1                         0.000   927       81
   C&S&R                        1.86 (1.39--2.50)                 178       16
   S&R                          1.27 (0.56--2.87)                 29        2
                                                                            
  Type of surgery                                                 1065      93
   MRM                          1                         0.000   649       57
   RM                           1.09 (0.64--1.86)                 62        5
   TM                           1.60 (1.13--2.28)                 99        9
   L                            0.58 (0.37--0.90)                 164       14
   Q                            0.32 (0.14--0.73)                 85        7
   PM                           2.66 (0.85--8.36)                 6         1

Abbreviations: IDC = Invasive Ductal Carcinoma, ILC = Invasive Lobular Carcinoma, Med.C = Medullary Carcinoma, MLDC = Mixed Lobular Ductal Carcinoma, Muc.C = Mucinous Carcinoma, IPC = Invasive Papillary Carcinoma, Met.C = Metaplastic Carcinoma, S&C&R = Surgery and Chemotherapy and Radiotherapy, C&S&R = Chemotherapy and Surgery and Radiotherapy, S&R = Surgery and Radiotherapy, MRM = Modified Radical Mastectomy, RM = radical Mastectomy, TM = Total Mastectomy, L = Lumpectomy, Q = Quadrantectomy, PM = Partial Mastectomy

We modeled all statistically significant variables of the three previous models together to explore how the effect of socio-demographic variables might influence survival. This analysis showed that while the effect estimates for all variables were virtually unchanged, the socio-demographic variables and bone and lung metastases became non-significant. (Table [2](#T2){ref-type="table"}) We interpret this as showing that the effects of the real and measurable effects of socio-demographic factors on survival were expressed in tumour characteristics.

Using the life-table method, five-year overall survival of this study population was 58% (95%CI; 53%--62%). The three-year overall survival was 76% (95%CI; 73%--79%).

There was no evidence that the proportional hazards assumption was violated in any of the analyses reported above.

Discussion
==========

This study has shown that of all socioeconomic factors only family income was associated with survival after adjustment for other factors. This is in agreement with other studies which obtained family income data by interviewing patients \[[@B11]-[@B13]\] as in this study. However, other studies which have obtained income data from a census have shown no association \[[@B2],[@B14],[@B15]\].

Of all demographic factors assessed, only smoking was related to breast cancer prognosis in this study, showing an adverse effect on survival which remained significant after adjustment for income. Two other studies in the UK and Sweden found a similar result \[[@B16],[@B17]\]. It is perhaps surprising that income remains significant after adjusting for smoking. This may be a true effect or may be due to inadequate control for smoking using the binary data available -- smoker/non-smoker. Exploratory analysis provided evidence that the effects of smoking and income on survival were mediated through adverse tumour characteristics.

The impact of young age at diagnosis on breast cancer survival has been long debated. This study found no evidence of a relationship between younger age at diagnosis and survival. Moreover age at diagnosis was not related to tumour characteristics. These findings accord with some studies \[[@B13],[@B18],[@B19]\] but not others \[[@B20],[@B21]\] although in the latter studies the age categorization and settings were different.

BMI was not significantly related to survival in agreement with Carmichael\'s study in 2004 \[[@B22]\]. However four other studies reported a higher risk of death in patients with BMI \> 30 compared to those with BMI \< 25 \[[@B23]-[@B25]\]. The differences in findings for BMI in our study could be due to their late stage diagnosis for our study population.

This study found no evidence for a relationship between family history of breast cancer and survival and also observed that patients with positive and negative family history had similar tumour characteristics. This is consistent with the results of several other studies \[[@B21],[@B26],[@B27]\]. Our findings revealed that tumour size, histological grade, and lymph node status were associated with breast cancer survival after mutual adjustment. This result is consistent with some other studies \[[@B28],[@B29]\]. We found that poorly differentiated tumours carried a higher risk of death compared to well-differentiated tumours. Patients with tumour size 5 cm and above had a higher risk of death than those with tumour size 2 cm and less.

In this study lymph node status was investigated in three different ways: number of involved nodes, lymph node ratio, and number of excised nodes. The number of involved nodes and lymph node ratio were the most powerful predictors of survival on multifactorial analysis. According to our findings not only did node positive patients have a poorer survival rate compared to node negatives, but also as the number of involved nodes increased the risk of death increased too. A similar trend has been reported elsewhere \[[@B30],[@B31]\]. Lymph node ratio (LNR) was negatively correlated with survival in agreement with studies from Canada \[[@B32]\], Belgium \[[@B33],[@B34]\] and the USA \[[@B35]\]. The number of excised lymph nodes was non-significant after adjustment for other pathological factors.

This study found no association between histological type and survival in common with other works \[[@B29],[@B36]\]. We found no evidence for an effect of intra-mammary tumour location. However, three studies reported an adverse effect of medial location \[[@B37],[@B38]\], and three others reported that central location was a negative predictor of survival \[[@B39],[@B40]\] compared to other locations. These differences might be due to missing data in our study since data regarding tumour location was only available for about one-third of the women. Skin and nipple involvement, tumour calcification and necrosis, vascular and lymphatic invasion were negatively associated with survival, but these effects became non-significant after adjustment. We note that these factors were closely correlated with each other and also with tumour size and grade, and lymph node status which may explain our findings.

Patients who underwent surgery as the first treatment option had a better prognosis than those who were treated firstly by chemotherapy. It might be due to a larger tumour size; because, women with larger tumours or metastatic diseases at diagnosis were mostly treated with chemotherapy followed by surgery. Moreover, all patients with tumour size above 1 cm received chemotherapy, which is a standard practice at the institution of study. This practice may not be standard elsewhere and this difference in treatment may contribute to the relatively poor prognosis seen.

Most other studies have reported significant effects on survival of tumour size, histological grade, and lymph node status but for other pathological factors. Our findings differed a little which could be due to the adjustment we performed -- other studies have tended to adjust for only a few pathological factors whereas in our study we included 13 pathological factors that were significantly associated with survival in unifactorial analysis.

Three- and five-year overall survival rates in southern Iran were found to be 76% and 58%, respectively. To our knowledge only two studies have previously reported 5-year overall breast cancer survival rates in Iran and these were 60% \[[@B9]\] and 62% \[[@B10]\]. These studies were conducted in Tehran. The 5-year overall survival rates in Iran compare with 46% in India \[[@B41]\], 64% in Oman \[[@B4]\], 65% in Greece \[[@B42]\], 71% in Germany \[[@B43]\], 78% in Belgium \[[@B41]\], 89% in the USA \[[@B44]\], and 84% in the UK \[[@B45]\] and show that Iran has considerably poorer survival than European countries and the United States.

There are several possible reasons for this. In Iran women\'s awareness of breast cancer is limited -- Iranian women have little or no information regarding breast self examination and its effect on early detection and prognosis. A study of health staff in Tehran found that only 6 percent of them reported doing breast self examination on a regular basis \[[@B46]\] and a study in Middle Eastern Asian Islamic immigrant women in the USA reported that none did regular breast self-examination \[[@B47]\]. Although, Hackshaw, 2003, concluded that breast self-examination cannot improve survival after breast cancer, women who do it, are more aware of changes in their breast and seek care earlier if there is any problem \[[@B48]\].

There are strong cultural barriers which hinder Iranian women from consulting with a physician for sensitive female-specific health problems. Even highly educated women are reluctant to seek treatment for breast tumours. Further to this, access to cancer treatment units is slow, delaying diagnosis and there is no screening mammography. It seems probable that all of these factors increase the chances of delayed diagnosis and hence late stage disease which is the main difference between Iranian women and women in Western countries.

There are some limitations to this study. Data for some explanatory factors were missing and some were recorded in a wrong way that made them less useful. For example, for age at first pregnancy data were available for 122 patients and for OCP usage it was available for 255 patients. In relation to OCP usage it was recorded as usage of OCP for three years and less and for above three years. It was not clear whether the others had never used OCP or they had used it but they were not asked for any information. A proportion of subjects had received hormonal therapy, but no data regarding hormone receptor status and hormonal therapy were recorded in the registry and so this factor could not be investigated. Also the type of chemotherapy drugs, doses, and duration of chemotherapy was not recorded at the registry and was not analyzed in this study.

In relation to preexisting diseases, only one disease was recorded for each patient per GP visit and so there were no data on any other preexisting diseases. In addition, preexisting diseases were categorized into five categories: gastrointestinal and respiratory, cardiovascular, psychological and neurological, gynaecological, endocrine and metabolic. This categorization differs from the international classification of diseases, and other diseases such as musculoskeletal and skin diseases were not considered. Again it was not clear whether the patients did not have these diseases or they had but it was not recorded. All of these limitations have since been addressed for future data collection but cannot be remedied for the current study.

It is strength and a weakness that this is the first study based on cancer registry data in Shiraz University of Medical Sciences, where full data collection was begun in 2000. The strengths lie in the richness of the data with many potential predictor variables tested and the uniqueness of the findings for this population. The weakness is that only 5 years of data were available for analysis, giving a relatively small sample size of 1148 women. This therefore limits the statistical power of the study. With 1148 women and power 90%, significance level 5%, a hazard ratio of 1.4 can be detected. Therefore we acknowledge that this study has insufficient statistical power to detect effects which are smaller than this and so it is possible that smaller effects have been missed. In future years when more data have been gathered, power will be greater and smaller effects can be estimated with greater confidence. In addition, in future years, the follow-up period will be longer allowing survival to be estimated with greater precision and to allow the estimation of survival beyond the 5 years possible at this time.

Conclusion
==========

In conclusion, the results presented in this study demonstrate a relatively low five-year overall survival rate for women diagnosed with breast cancer in Iran. Following the analysis of 44 explanatory factors, the results presented in this study suggests that survival from breast cancer in southern Iran is affected by delayed diagnosis and therefore late stage disease. We hypothesize that this is due to low level of awareness, cultural barriers and slow access to treatment. Further research is needed in Iranian women to test these hypotheses and thus design appropriate interventions to ultimately improve survival.
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